Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.17%
0%
0.17%
6 Months
27.37%
0%
27.37%
1 Year
-27.51%
0%
-27.51%
2 Years
55.78%
0%
55.78%
3 Years
-74.96%
0%
-74.96%
4 Years
-88.4%
0%
-88.4%
5 Years
-98.12%
0%
-98.12%
RELIEF THERAPEUTICS Holding SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
38.25%
EBIT Growth (5y)
-157.35%
EBIT to Interest (avg)
-21.65
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.10
Tax Ratio
11.56%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.26
EV to EBIT
-3.49
EV to EBITDA
-4.51
EV to Capital Employed
1.41
EV to Sales
7.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-40.51%
ROE (Latest)
-13.48%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Dec 2023
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 7 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
8.40
6.00
40.00%
Operating Profit (PBDIT) excl Other Income
-5.10
-16.60
69.28%
Interest
0.10
0.20
-50.00%
Exceptional Items
-12.60
-91.10
86.17%
Consolidate Net Profit
-17.10
-98.20
82.59%
Operating Profit Margin (Excl OI)
-911.10%
-3,299.20%
238.81%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 40.00% vs -1.64% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 82.59% vs -93.31% in Dec 2023
About RELIEF THERAPEUTICS Holding SA 
RELIEF THERAPEUTICS Holding SA
Pharmaceuticals & Biotechnology
RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
Company Coordinates 
Company Details
Fondation EIP, Batiment F2/F3, Avenue de Secheron 15 GENEVE None : 1202
Registrar Details






